Hepatitis C virus serotype II responds more favorably to interferon-alpha therapy

J Hepatol. 1994 Jul;21(1):130-2. doi: 10.1016/s0168-8278(94)80149-5.

Abstract

To determine whether serological typing of hepatitis C virus correlated with the response to interferon-alpha therapy, hepatitis C virus serotypes were determined by subtype-specific antibody to NS4 polypeptide by enzyme-linked immunosorbent assay in 55 Japanese patients with chronic active hepatitis C who subsequently received recombinant interferon-alpha 2a therapy. Response to interferon-alpha was defined as complete and sustained (n = 12), complete response followed by relapse (n = 26), and no response (n = 17). There was no difference in the clinical biochemical parameters between these patients groups. However, a higher proportion (50.0%) of patients with hepatitis C virus serotype II showed complete and sustained response to interferon-alpha, compared to serotype I (11.1%, p < 0.01). These data indicate that this simple hepatitis C virus serotyping assay is a useful predictor of response to interferon-alpha therapy in patients with chronic hepatitis C virus infection.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepacivirus / classification*
  • Hepacivirus / immunology
  • Hepatitis Antibodies / blood
  • Hepatitis C / blood
  • Hepatitis C / classification
  • Hepatitis C / therapy*
  • Hepatitis C Antibodies
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Predictive Value of Tests
  • RNA, Viral / blood
  • Recombinant Proteins
  • Serotyping

Substances

  • Hepatitis Antibodies
  • Hepatitis C Antibodies
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins